» Articles » PMID: 38378992

Cyclin-dependent Kinase 5 and Neurodegenerative Diseases

Overview
Journal Mol Neurobiol
Date 2024 Feb 21
PMID 38378992
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative diseases are a group of diseases characterized by the progressive loss of neurons, including Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis. These diseases have a high incidence and mortality rate globally, placing a heavy burden on patients and their families. The pathogenesis of neurodegenerative diseases is complex, and there are no effective treatments at present. Cyclin-dependent kinase 5 is a proline-directed serine/threonine protein kinase that is closely related to the development and function of the nervous system. Under physiological conditions, it is involved in regulating the process of neuronal proliferation, differentiation, migration, and synaptic plasticity. Moreover, there is increasing evidence that cyclin-dependent kinase 5 also plays an important role in the pathogenesis of neurodegenerative diseases. In this review, we address the biological characteristics of cyclin-dependent kinase 5 and its role in neurodegenerative diseases. In particular, this review highlights the underlying mechanistic linkages between cyclin-dependent kinase 5 and mitochondrial dysfunction, oxidative stress and neuroinflammation in the context of neurodegeneration. Finally, we also summarize the currently available cyclin-dependent kinase 5 inhibitors and their prospects for the treatment of neurodegenerative diseases. Taken together, a better understanding of the molecular mechanisms of cyclin-dependent kinase 5 involved in neurodegenerative diseases can lead to the development of new strategies for the prevention and treatment of these devastating diseases.

Citing Articles

Editorial: Protein kinase inhibitors in neurodegeneration and cancer targeted therapies.

Anwar S, Ahmed A, Sarli V, Hassan I Front Cell Dev Biol. 2024; 12:1413293.

PMID: 38699160 PMC: 11063359. DOI: 10.3389/fcell.2024.1413293.

References
1.
Wilson 3rd D, Cookson M, Van Den Bosch L, Zetterberg H, Holtzman D, Dewachter I . Hallmarks of neurodegenerative diseases. Cell. 2023; 186(4):693-714. DOI: 10.1016/j.cell.2022.12.032. View

2.
Hisanaga S, Endo R . Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem. 2010; 115(6):1309-21. DOI: 10.1111/j.1471-4159.2010.07050.x. View

3.
Paoletti P, Vila I, Rife M, Lizcano J, Alberch J, Gines S . Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci. 2008; 28(40):10090-101. PMC: 6671267. DOI: 10.1523/JNEUROSCI.3237-08.2008. View

4.
Su S, Tsai L . Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol. 2011; 27:465-91. DOI: 10.1146/annurev-cellbio-092910-154023. View

5.
Wilkaniec A, Gassowska-Dobrowolska M, Strawski M, Adamczyk A, Czapski G . Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. J Neuroinflammation. 2018; 15(1):1. PMC: 5753486. DOI: 10.1186/s12974-017-1027-y. View